Twist Bioscience (TWST) Accumulated Expenses (2018 - 2026)

Twist Bioscience has disclosed Accumulated Expenses across 9 years of filings, most recently posting $27.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 8.36% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $27.0 million (up 8.36% YoY), while the FY2025 annual figure was $31.3 million, up 107.15% from the prior year.
• Accumulated Expenses rose to $27.0 million in Q1 2026, from $18.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for TWST reached as high as $31.7 million in Q2 2024 and fell as low as $10.3 million in Q2 2023.
• The 5-year median for Accumulated Expenses is $24.3 million (2023), against an average of $22.1 million.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 469.1% — and 2023, when it tumbled 62.77%.
• A 5-year view of Accumulated Expenses shows it stood at $23.3 million in 2022, then tumbled by 40.03% to $14.0 million in 2023, then soared by 44.2% to $20.1 million in 2024, then declined by 6.43% to $18.8 million in 2025, then jumped by 43.37% to $27.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $27.0 million, $18.8 million, and $31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.